In one paragraphArticle in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
21 authors.
Liliane El EidSection of Cell Biology and Functional Genomics, Division of Diabetes, Endocrinology and Metabolism, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.ORCID 0000-0002-6511-6210 Yusman ManchandaSection of Cell Biology and Functional Genomics, Division of Diabetes, Endocrinology and Metabolism, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.ORCID 0000-0002-2874-5608 Gregory AustinSection of Cell Biology and Functional Genomics, Division of Diabetes, Endocrinology and Metabolism, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.
Kieran Deane-AlderDrug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.ORCID 0000-0003-2762-2240 Zamara MariamCentre for Health and Life Sciences, Coventry University, Coventry, UK.
Affiong I OquaSection of Cell Biology and Functional Genomics, Division of Diabetes, Endocrinology and Metabolism, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.ORCID 0000-0002-0584-120X Matthew J BelousoffDrug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.ORCID 0000-0002-3229-474X Kyle W SloopDiabetes, Obesity and Complications, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA.ORCID 0000-0001-6748-9929 Guy A RutterSection of Cell Biology and Functional Genomics, Division of Diabetes, Endocrinology and Metabolism, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.ORCID 0000-0001-6360-0343 Steven J MillershipSection of Cell Biology and Functional Genomics, Division of Diabetes, Endocrinology and Metabolism, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.ORCID 0000-0001-6947-7059 Ben JonesSection of Endocrinology and Investigative Medicine, Division of Diabetes, Endocrinology and Metabolism, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.ORCID 0000-0003-0461-2584 Patrick M SextonDrug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.ORCID 0000-0001-8902-2473 Denise WoottenDrug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.ORCID 0000-0003-4563-1642 Alejandra TomasSection of Cell Biology and Functional Genomics, Division of Diabetes, Endocrinology and Metabolism, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.ORCID 0000-0002-2290-8453 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are effective therapies for type 2 diabetes (T2D) and obesity, yet patient responses are variable, with
Indexed as
Glucagon-Like Peptide-1 ReceptorMutation, MissenseAnimalsBlood GlucoseDiabetes Mellitus, Type 2Glucagon-Like Peptide-1 Receptor AgonistsHumansInsulin-Secreting CellsMaleMiceMolecular Dynamics SimulationProtein ConformationBlood GlucoseGLP1R protein, humanGlucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide-1 Receptor Agonists
Identifiers
PMID41637494
PMCPMC13267291
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390